Actinium Pharmaceuticals, Inc.  (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37th Annual Roth Conference on March 16th ...

Precigen's PRGN-2012 and UltraCAR-Ts offer groundbreaking therapies. Read why PGEN stock is a strong pick, with major ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Fintel reports that on March 5, 2025, Jefferies downgraded their outlook for Chimerix (NasdaqGM:CMRX) from Buy to Hold.

The 5-year relative survival rate for AML is 31.9%. Chronic myeloid leukemia ... cells in your body as possible and reduce the risk of recurrence (the cancer coming back). What questions should ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 ...

City of Hope® Research Spotlight offers a glimpse at groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...

She began a pioneering study of Hodgkin lymphoma, which led to refinements in therapy that allowed certain patients, based on specific characteristics, to receive less radiation or forgo it all ...

Patient 2 was a 49-year-old man diagnosed with acute myeloid leukemia. He underwent haploidentical allo-HSCT from his son and did not develop GVHD. At 23 months post-transplant, the patient ...

HealthDay News — For patients with systemic lupus erythematosus (SLE) and pericarditis, recurrence of pericarditis occurs in more than 20 percent of patients and associated factors include younger age ...